Plasmapheresis Decreases Belatacept Exposure: Requires Consideration for Dose and Frequency Adjustments

Belatacept was approved for kidney transplantation (KTx) in 2011. Belatacept has a long half life (9.8 d) with a small volume of distribution (0.09 L/k). After KTx, patients may require plasmapheresis (PP). However, the effects of PP on belatacept serum concentrations have not been reported. The aim of the present report is to examine the changes in serum concentration of belatacept with each PP in between belatacept dosing.

This is a non-final version of an article published in final form in Transplantation.

Files

Metadata

Work Title Plasmapheresis Decreases Belatacept Exposure: Requires Consideration for Dose and Frequency Adjustments
Access
Open Access
Creators
  1. Ashokkumar Jain
  2. Ruichao Xu
  3. Raman Venkataramanan
  4. Umar Farooq
  5. Fauzia Butt
  6. Nasrollah Ghahramani
  7. Zakiyah Kadry
Keyword
  1. belatacept
  2. plasmapheresis
  3. kidney transplantation
License In Copyright (Rights Reserved)
Work Type Article
Publisher
  1. Transplantation
Publication Date October 2021
Publisher Identifier (DOI)
  1. 10.1097/TP.0000000000003840
Deposited December 10, 2021

Versions

Analytics

Collections

This resource is currently not in any collection.

Work History

Version 1
published

  • Created
  • Added Creator Ashokkumar Jain
  • Added Creator Ruichao Xu
  • Added Creator Raman Venkataramanan
  • Added Creator Umar Farooq
  • Added Creator Fauzia Butt
  • Added Creator Nasrollah Ghahramani
  • Added Creator Zakiyah Kadry
  • Added Belatacept_first_TPA-2021-0250_R2__2_.pdf
  • Updated License Show Changes
    License
    • https://rightsstatements.org/page/InC/1.0/
  • Published
  • Updated
  • Updated